Replies to post #136521 on Biotech Values

[vinmantoo]

jq1234,

I definitely agree with you. If EXEL were a larger company, they would have worked out a narrower range of CABO dosages before proceeding. As a small company, EXEL didn't have the luxury of time.

For once I made buys and the stocks didn't to go. I bought more EXEL about a week ago at $5 and more MNTA at $15. Maybe this is a new year after all.